Additionally, in the DIO mouse model, GFAP expression in the prefrontal cortex, which is one of the regions in the brain linked to cognitive decline observed in obesity [26], was lower in DIO mice treated with CYR119 than in the DIO-control mice. Here, GFAP is linked to obesity disorder.